Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointments of J. Kevin Buchi, former chief executive officer of Cephalon, Inc., and TetraLogic Pharmaceuticals Corp., and Cynthia Smith, former chief commercial officer of ZS Pharma, Inc., to its board of directors
August 16, 2018
· 4 min read